BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
- Author
- LI, D1 2 ; AMBROGIO, L1 3 ; RETTIG, W. J7 ; MEYERSON, M1 3 4 ; SOLCA, F7 ; GREULICH, H1 3 4 ; WONG, K.-K1 4 ; SHIMAMURA, T1 4 ; KUBO, S5 ; TAKAHASHI, M5 ; CHIRIEAC, L. R6 ; PADERA, R. F6 ; SHAPIRO, G. I1 4 ; BAUM, A7 ; HIMMELSBACH, F8
[1] Department of Medical Oncology, Dana-Farber Cancer Institute, MA, United States
[2] Ludwig Center at Dana-Farber/Harvard Cancer Center, Boston, MA, United States
[3] The Broad Institute of Harvard and MIT, Cambridge, MA, United States
[4] Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, United States
[5] Department of Radiology, Beth Israel Deaconess Medical Center, Boston, MA, United States
[6] Department of Pathology, Brigham and Women's Hospital, Boston, MA, United States
[7] Boehringer Ingelheim Austria, Vienna, Austria
[8] Boehringer Ingelheim Pharma, Biberach, Germany - Source
Oncogene (Basingstoke). 2008, Vol 27, Num 34, pp 4702-4711, 10 p ; ref : 3/4 p
- ISSN
- 0950-9232
- Scientific domain
- Cell biology, histology; Medical oncology; Genetics
- Publisher
- Nature Publishing, Basingstoke
- Publication country
- United Kingdom
- Document type
- Article
- Language
- English
- Author keyword
- BIBW2992 EGFR HER2 lung cancer therapeutics
- Keyword (fr)
- Cancer du poumon Carcinogenèse Gène onc cellulaire Inhibiteur Modèle Cancer Pathologie de l'appareil respiratoire Pathologie des bronches Pathologie des poumons Tumeur maligne
- Keyword (en)
- Lung cancer Carcinogenesis C-Onc gene Inhibitor Models Cancer Respiratory disease Bronchus disease Lung disease Malignant tumor
- Keyword (es)
- Cáncer del pulmón Carcinogénesis Gen onc celular Inhibidor Modelo Cáncer Aparato respiratorio patología Bronquio patología Pulmón patología Tumor maligno
- Classification
- Pascal
- 002 Biological and medical sciences / 002A Fundamental and applied biological sciences. Psychology / 002A04 Molecular and cellular biology / 002A04H Cell physiology / 002A04H04 Cell transformation and carcinogenesis. Action of oncogenes and antioncogenes
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B11 Pneumology / 002B11A Tumors of the respiratory system and mediastinum
- Discipline
- Molecular and cell biology Pulmonology
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 20588930
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1038/onc.2008.109 
https://dx.doi.org/10.1038/onc.2008.109
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:20:\"10.1038\/onc.2008.109\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:96:\"BIBW2992, an irreversible EGFR\/HER2 inhibitor highly effective in preclinical lung cancer models\";s:9:\"\u0000*\u0000jtitle\";s:22:\"Oncogene (Basingstoke)\";s:9:\"\u0000*\u0000stitle\";s:22:\"Oncogene (Basingstoke)\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:2:\"27\";s:8:\"\u0000*\u0000issue\";s:2:\"34\";s:8:\"\u0000*\u0000spage\";s:4:\"4702\";s:8:\"\u0000*\u0000epage\";s:4:\"4711\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0950-9232\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:2:\"LI\";s:10:\"\u0000*\u0000aufirst\";s:1:\"D\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:14:{i:0;s:11:\"AMBROGIO, L\";i:1;s:12:\"RETTIG, W. J\";i:2;s:11:\"MEYERSON, M\";i:3;s:8:\"SOLCA, F\";i:4;s:11:\"GREULICH, H\";i:5;s:10:\"WONG, K.-K\";i:6;s:12:\"SHIMAMURA, T\";i:7;s:7:\"KUBO, S\";i:8;s:12:\"TAKAHASHI, M\";i:9;s:14:\"CHIRIEAC, L. R\";i:10;s:12:\"PADERA, R. F\";i:11;s:13:\"SHAPIRO, G. I\";i:12;s:7:\"BAUM, A\";i:13;s:14:\"HIMMELSBACH, F\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:96:\"BIBW2992, an irreversible EGFR\/HER2 inhibitor highly effective in preclinical lung cancer models\";s:8:\"\u0000*\u0000place\";s:11:\"Basingstoke\";s:6:\"\u0000*\u0000pub\";s:17:\"Nature Publishing\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:20:\"10.1038\/onc.2008.109\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:96:\"BIBW2992, an irreversible EGFR\/HER2 inhibitor highly effective in preclinical lung cancer models\";s:9:\"\u0000*\u0000jtitle\";s:22:\"Oncogene (Basingstoke)\";s:9:\"\u0000*\u0000stitle\";s:22:\"Oncogene (Basingstoke)\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:2:\"27\";s:8:\"\u0000*\u0000issue\";s:2:\"34\";s:8:\"\u0000*\u0000spage\";s:4:\"4702\";s:8:\"\u0000*\u0000epage\";s:4:\"4711\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0950-9232\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:2:\"LI\";s:10:\"\u0000*\u0000aufirst\";s:1:\"D\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:14:{i:0;s:11:\"AMBROGIO, L\";i:1;s:12:\"RETTIG, W. J\";i:2;s:11:\"MEYERSON, M\";i:3;s:8:\"SOLCA, F\";i:4;s:11:\"GREULICH, H\";i:5;s:10:\"WONG, K.-K\";i:6;s:12:\"SHIMAMURA, T\";i:7;s:7:\"KUBO, S\";i:8;s:12:\"TAKAHASHI, M\";i:9;s:14:\"CHIRIEAC, L. R\";i:10;s:12:\"PADERA, R. F\";i:11;s:13:\"SHAPIRO, G. I\";i:12;s:7:\"BAUM, A\";i:13;s:14:\"HIMMELSBACH, F\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:96:\"BIBW2992, an irreversible EGFR\/HER2 inhibitor highly effective in preclinical lung cancer models\";s:8:\"\u0000*\u0000place\";s:11:\"Basingstoke\";s:6:\"\u0000*\u0000pub\";s:17:\"Nature Publishing\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:20:\"10.1038\/onc.2008.109\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:20:\"10.1038\/onc.2008.109\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:96:\"BIBW2992, an irreversible EGFR\/HER2 inhibitor highly effective in preclinical lung cancer models\";s:9:\"\u0000*\u0000jtitle\";s:22:\"Oncogene (Basingstoke)\";s:9:\"\u0000*\u0000stitle\";s:22:\"Oncogene (Basingstoke)\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:2:\"27\";s:8:\"\u0000*\u0000issue\";s:2:\"34\";s:8:\"\u0000*\u0000spage\";s:4:\"4702\";s:8:\"\u0000*\u0000epage\";s:4:\"4711\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0950-9232\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:2:\"LI\";s:10:\"\u0000*\u0000aufirst\";s:1:\"D\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:14:{i:0;s:11:\"AMBROGIO, L\";i:1;s:12:\"RETTIG, W. J\";i:2;s:11:\"MEYERSON, M\";i:3;s:8:\"SOLCA, F\";i:4;s:11:\"GREULICH, H\";i:5;s:10:\"WONG, K.-K\";i:6;s:12:\"SHIMAMURA, T\";i:7;s:7:\"KUBO, S\";i:8;s:12:\"TAKAHASHI, M\";i:9;s:14:\"CHIRIEAC, L. R\";i:10;s:12:\"PADERA, R. F\";i:11;s:13:\"SHAPIRO, G. I\";i:12;s:7:\"BAUM, A\";i:13;s:14:\"HIMMELSBACH, F\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:96:\"BIBW2992, an irreversible EGFR\/HER2 inhibitor highly effective in preclinical lung cancer models\";s:8:\"\u0000*\u0000place\";s:11:\"Basingstoke\";s:6:\"\u0000*\u0000pub\";s:17:\"Nature Publishing\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:20:\"10.1038\/onc.2008.109\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:96:\"BIBW2992, an irreversible EGFR\/HER2 inhibitor highly effective in preclinical lung cancer models\";s:9:\"\u0000*\u0000jtitle\";s:22:\"Oncogene (Basingstoke)\";s:9:\"\u0000*\u0000stitle\";s:22:\"Oncogene (Basingstoke)\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:2:\"27\";s:8:\"\u0000*\u0000issue\";s:2:\"34\";s:8:\"\u0000*\u0000spage\";s:4:\"4702\";s:8:\"\u0000*\u0000epage\";s:4:\"4711\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0950-9232\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:2:\"LI\";s:10:\"\u0000*\u0000aufirst\";s:1:\"D\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:14:{i:0;s:11:\"AMBROGIO, L\";i:1;s:12:\"RETTIG, W. J\";i:2;s:11:\"MEYERSON, M\";i:3;s:8:\"SOLCA, F\";i:4;s:11:\"GREULICH, H\";i:5;s:10:\"WONG, K.-K\";i:6;s:12:\"SHIMAMURA, T\";i:7;s:7:\"KUBO, S\";i:8;s:12:\"TAKAHASHI, M\";i:9;s:14:\"CHIRIEAC, L. R\";i:10;s:12:\"PADERA, R. F\";i:11;s:13:\"SHAPIRO, G. I\";i:12;s:7:\"BAUM, A\";i:13;s:14:\"HIMMELSBACH, F\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:96:\"BIBW2992, an irreversible EGFR\/HER2 inhibitor highly effective in preclinical lung cancer models\";s:8:\"\u0000*\u0000place\";s:11:\"Basingstoke\";s:6:\"\u0000*\u0000pub\";s:17:\"Nature Publishing\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:20:\"10.1038\/onc.2008.109\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:96:\"BIBW2992, an irreversible EGFR\/HER2 inhibitor highly effective in preclinical lung cancer models\";s:9:\"\u0000*\u0000jtitle\";s:22:\"Oncogene (Basingstoke)\";s:9:\"\u0000*\u0000stitle\";s:22:\"Oncogene (Basingstoke)\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:2:\"27\";s:8:\"\u0000*\u0000issue\";s:2:\"34\";s:8:\"\u0000*\u0000spage\";s:4:\"4702\";s:8:\"\u0000*\u0000epage\";s:4:\"4711\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0950-9232\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:2:\"LI\";s:10:\"\u0000*\u0000aufirst\";s:1:\"D\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:14:{i:0;s:11:\"AMBROGIO, L\";i:1;s:12:\"RETTIG, W. J\";i:2;s:11:\"MEYERSON, M\";i:3;s:8:\"SOLCA, F\";i:4;s:11:\"GREULICH, H\";i:5;s:10:\"WONG, K.-K\";i:6;s:12:\"SHIMAMURA, T\";i:7;s:7:\"KUBO, S\";i:8;s:12:\"TAKAHASHI, M\";i:9;s:14:\"CHIRIEAC, L. R\";i:10;s:12:\"PADERA, R. F\";i:11;s:13:\"SHAPIRO, G. I\";i:12;s:7:\"BAUM, A\";i:13;s:14:\"HIMMELSBACH, F\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:96:\"BIBW2992, an irreversible EGFR\/HER2 inhibitor highly effective in preclinical lung cancer models\";s:8:\"\u0000*\u0000place\";s:11:\"Basingstoke\";s:6:\"\u0000*\u0000pub\";s:17:\"Nature Publishing\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
